have demonstrated that in models of both primary and secondary HLH, JAK1/2 inhibition was superior to IFNγ-blocking alone in dampening inflammatory biomarkers, improving clinical parameters and enhancing survival. This evidence concerns the gene IFNG and hemophagocytic syndrome.